The Economic Times
12,129.5073.7
Stock Analysis, IPO, Mutual Funds, Bonds & More

NPPA hikes 21 formulations’ prices by 50%

The National Pharmaceuticals Pricing Authority (NPPA) invoked paragraph 19 of the Drug Prices Control Order to grant a 50% increase in the prices of 21 drug formulations. With the cost of raw material imported from China increasing 50-200%, pharma groups had approached the government to invoke extraordinary powers and increase the prices of drugs.

ET Bureau|
Last Updated: Dec 14, 2019, 07.08 AM IST|Original: Dec 14, 2019, 07.08 AM IST
0Comments
ThinkStock Photos
pills-hnkstck
New Delhi: India invoked extraordinary powers in public interest for the first time to grant a 50% increase in the prices of 21 drug formulations, including ascorbic acid (Vitamin C) tablets, certain antibiotic tablets and syrups, medicines to treat leprosy and malaria and BCG vaccines, citing higher ingredient costs.

The National Pharmaceuticals Pricing Authority (NPPA) invoked paragraph 19 of the Drug Prices Control Order, which until now has been used only to reduce the prices of stents and knee implants.

Industry lobby groups had met senior officials of the Department of Pharmaceuticals, urging them to increase the prices of these formulations, ET had reported on December

12. NPPA deliberated upon the matter and issued the notification on Friday.

With the cost of raw material imported from China increasing 50-200%, pharmaceutical lobby groups had approached the government to invoke extraordinary powers and increase the prices of drugs.

Over 70% of India’s bulk drug requirement comes from China. These bulk drugs or active pharmaceutical ingredients (API) are used to produce medicines, including antibiotics, vitamins and folic acid.

Noting that these formulations are “low priced drugs and have been under repeated price control,” NPPA invoked the extraordinary powers in public interest for “upward revision of ceiling prices of the 21 scheduled formulations of 12 drugs.”

Most of these drugs are used as the first line of treatment and are crucial to the public health programme of the country, the NPPA said.

“The one-time 50% price increase is arbitrary. The government needs to put in place a system for monitoring API prices and fluctuations,” said S Srinivasan, co-convenor of All India Drugs Action Network.

Also Read

NPPA defers decision on Meril’s stent pricing plea

Violation of drug price control order: Drug cos under NPPA lens for self-exemption from price cap

NPPA approves hike in prices of coronary stents

NPPA fixes retail price of 68 drug formulations

Comments
Add Your Comments
Commenting feature is disabled in your country/region.

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service